Under the deal, Twist Biopharma will collaborate with Serotiny to discover novel chimeric antigen receptors (CAR) for CAR T-cell therapies. The firm will provide Serotiny with custom DNA libraries that encode CARs. Serotiny will then engineer and characterize unique CARs on a large scale to screen for receptor designs that offer improved therapeutic properties and applicability to a wide range of solid tumors, according to the company. Twist will be able to license any technology resulting from the collaboration.
In its partnership with Applied StemCell, Twist will add the firm's Targatt Chinese hamster ovary (CHO) cell lines for screening, selecting, and characterizing any antibodies discovered for its partnered and internal programs.
Copyright © 2021 scienceboard.net